MCP-1 was ranked third in the XGBoost model (Figure 10); this is also in agreement with the findings of other groups where MCP-1 expression levels were found to be higher in patients with COVID-19, especially those admitted to intensive care units (54). This evidence concerns the gene CCL2 and COVID-19.